Phase I Study of SHR-A2102 in Patients With Advanced Solid Tumors
Trial Parameters
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
Brief Summary
The study was designed to evaluate the efficacy, safety, and pharmacokinetics of SHR2102 in patients with advanced solid tumors. The objective of this study was to determine the dose-limiting toxicity, maximum tolerance and recommended dose of SHR-A2102 in phase II study.
Eligibility Criteria
Inclusion Criteria: 1. Able and willing to provide a written informed consent; 2. Age ≥18 years old, gender unlimited; 3. The physical status score of the Eastern Tumor Cooperative Group (ECOG) was 0 \~ 1; 4. Life expectancy Predicted survival ≥3 months; 5. Histologically or cytologically confirmed advanced or metastatic malignant tumor; Patients with advanced solid tumors confirmed by pathology who have failed or been intolerant to standard treatment, have no standard treatment or refuse standard treatment; 6. There is at least one measurable lesion that meets the RECIST 1.1 criteria. Exclusion Criteria: 1. Plan to receive any other antitumor therapy during this trial; 2. Receiving other investigational drugs or treatments that are not on the market within 4 weeks prior to the initial administration of the study drug; 3. Received antitumor therapy such as chemotherapy, radiotherapy, biotherapy, targeted therapy, or immunotherapy within 4 weeks prior to first administration of the stud